Atreca, Inc. stock is up 0.42% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 December’s closed higher than November.
Atreca, Inc. discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues.